Department of Pharmacology and Therapy, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia.
Drug Des Devel Ther. 2022 Jul 20;16:2325-2339. doi: 10.2147/DDDT.S350913. eCollection 2022.
Metastasis causes approximately 90% of cancer-related deaths, including in cervical cancer patients. Uncontrolled cell proliferation, migration, and cancer stemness act as critical events in primary tumor growth and cancer metastasis progression in cervical cancer. Here, we investigated the anti-proliferative, anti-migration, and cancer stemness inhibition activity of N-phenyl pyrazoline derivatives against cervical cancer cells.
The chalcone and phenylhydrazine were used to synthesize the N-phenyl pyrazoline 2/5 (P2 and P5). The MTT, colony formation, and wound healing assays were performed to evaluate the N-phenyl pyrazoline effect in HeLa cells. The N-phenyl pyrazoline's protein target was predicted using SwissTargetPrediction and AutoDock Vina software. The Western blotting assay was performed to evaluate the target proteins. The public dataset analysis was used to confirm the clinical relevance of target protein in cervical cancer patients.
N-phenyl pyrazoline 2 and 5 were successfully synthesized. The N-phenyl pyrazolines 2 and 5 exhibit cytotoxic effect in HeLa cell line with 20.26 µM, 4.708 µM of IC respectively. Further study shows that the N-phenyl pyrazoline 5 suppresses the cell proliferation and migration ability of HeLa cell line in a dose-dependent manner. Target prediction and molecular docking reveal that EGFR and ERBB2 protein as the main target of the N-phenyl pyrazoline 5 compound. The N-phenyl pyrazoline 5 suppresses the EGFR expression level but not the total ERK1/2. Public data and GSEA analysis found that the EGFR high expression level is positively associated with poor survival, cancer metastasis-related signaling pathways, and cancer stem cell markers in cervical cancer patients. In addition, the N-phenyl pyrazoline 5 reduces the HeLa's tumorsphere size and cancer stem cell marker, CD133.
N-phenyl pyrazoline 5 suppresses the cell viability, proliferation, migration, and cancer stem cell-like phenotype of cervical cancer cells via EGFR inhibition.
转移是导致约 90%癌症相关死亡的原因,包括宫颈癌患者。在宫颈癌中,不受控制的细胞增殖、迁移和癌症干细胞特性是原发性肿瘤生长和癌症转移进展的关键事件。在这里,我们研究了 N-苯基吡唑啉衍生物对宫颈癌细胞的抗增殖、抗迁移和癌症干细胞抑制活性。
用查耳酮和苯肼合成了 N-苯基吡唑啉 2/5(P2 和 P5)。通过 MTT、集落形成和划痕愈合实验评估 N-苯基吡唑啉在 HeLa 细胞中的作用。使用 SwissTargetPrediction 和 AutoDock Vina 软件预测 N-苯基吡唑啉的蛋白靶标。通过 Western blot 实验评估靶蛋白。使用公共数据集分析来确认靶蛋白在宫颈癌患者中的临床相关性。
成功合成了 N-苯基吡唑啉 2 和 5。N-苯基吡唑啉 2 和 5 对 HeLa 细胞系表现出细胞毒性作用,IC 分别为 20.26 µM 和 4.708 µM。进一步的研究表明,N-苯基吡唑啉 5 以剂量依赖性方式抑制 HeLa 细胞系的细胞增殖和迁移能力。靶标预测和分子对接表明,EGFR 和 ERBB2 蛋白是 N-苯基吡唑啉 5 化合物的主要靶标。N-苯基吡唑啉 5 抑制 EGFR 表达水平,但不抑制总 ERK1/2。公共数据和 GSEA 分析发现,EGFR 高表达水平与宫颈癌患者的不良生存、癌症转移相关信号通路和癌症干细胞标志物呈正相关。此外,N-苯基吡唑啉 5 降低了 HeLa 的肿瘤球大小和癌症干细胞标志物 CD133。
N-苯基吡唑啉 5 通过抑制 EGFR 抑制宫颈癌细胞的细胞活力、增殖、迁移和癌症干细胞样表型。